中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2014年
1期
29-34
,共6页
徐媛媛%高丽%孙君重%丁一%徐绎涵%吕超%刘雯雯%王楠%王莉莉
徐媛媛%高麗%孫君重%丁一%徐繹涵%呂超%劉雯雯%王楠%王莉莉
서원원%고려%손군중%정일%서역함%려초%류문문%왕남%왕리리
白血病,髓样,急性%逆转录聚合酶链反应%癌基因蛋白质类,融合
白血病,髓樣,急性%逆轉錄聚閤酶鏈反應%癌基因蛋白質類,融閤
백혈병,수양,급성%역전록취합매련반응%암기인단백질류,융합
Leukemia,myeloid,acute%Reverse transcriptase polymerase chain reaction%Oncogene proteins,fusion
目的 探讨应用多重巢式逆转录聚合酶链反应(RT-nPCR)初筛急性髓系白血病(AML)融合基因的临床价值.方法 根据WHO2008 AML分型指南建立检测16种融合基因(AML1-EVI1、AML1-ETO、AML1-MDS1、AML1-MTG16、MLL-AF9、MLL-AF6、MLL-AF 10、MLL-ENL、MLL-MLL、PML-RARα、PLZF-RARα、NPM 1-RARα、CBFB-MYH11、DEK-CAN、SET-CAN、TLS-ERG)的RT-nPCR体系,对356例AML患者同时采用RT-nPCR和核型分析方法检测染色体交互易位情况,针对阳性患者进一步采用分离PCR(split-out PCR)和荧光原位杂交(FISH)方法进行验证.结果 在356例AML患者中相应融合基因阳性者172例,阳性率为48.31%,高于核型分析相应染色体易位检出率(31.46%)(x2=70.314,P<0.01).在少见和难以识别的染色体易位中,RT-nPCR比核型分析、FISH更具有优势(x2=96.074,P<0.01).结论 RT-nPCR可便捷、有效、准确地检测AML患者融合基因异常,作为AML初筛的检测手段为疾病诊断及疗效判定提供重要依据,同时也为微小残留病监测及预后评估提供重要信息.
目的 探討應用多重巢式逆轉錄聚閤酶鏈反應(RT-nPCR)初篩急性髓繫白血病(AML)融閤基因的臨床價值.方法 根據WHO2008 AML分型指南建立檢測16種融閤基因(AML1-EVI1、AML1-ETO、AML1-MDS1、AML1-MTG16、MLL-AF9、MLL-AF6、MLL-AF 10、MLL-ENL、MLL-MLL、PML-RARα、PLZF-RARα、NPM 1-RARα、CBFB-MYH11、DEK-CAN、SET-CAN、TLS-ERG)的RT-nPCR體繫,對356例AML患者同時採用RT-nPCR和覈型分析方法檢測染色體交互易位情況,針對暘性患者進一步採用分離PCR(split-out PCR)和熒光原位雜交(FISH)方法進行驗證.結果 在356例AML患者中相應融閤基因暘性者172例,暘性率為48.31%,高于覈型分析相應染色體易位檢齣率(31.46%)(x2=70.314,P<0.01).在少見和難以識彆的染色體易位中,RT-nPCR比覈型分析、FISH更具有優勢(x2=96.074,P<0.01).結論 RT-nPCR可便捷、有效、準確地檢測AML患者融閤基因異常,作為AML初篩的檢測手段為疾病診斷及療效判定提供重要依據,同時也為微小殘留病鑑測及預後評估提供重要信息.
목적 탐토응용다중소식역전록취합매련반응(RT-nPCR)초사급성수계백혈병(AML)융합기인적림상개치.방법 근거WHO2008 AML분형지남건립검측16충융합기인(AML1-EVI1、AML1-ETO、AML1-MDS1、AML1-MTG16、MLL-AF9、MLL-AF6、MLL-AF 10、MLL-ENL、MLL-MLL、PML-RARα、PLZF-RARα、NPM 1-RARα、CBFB-MYH11、DEK-CAN、SET-CAN、TLS-ERG)적RT-nPCR체계,대356례AML환자동시채용RT-nPCR화핵형분석방법검측염색체교호역위정황,침대양성환자진일보채용분리PCR(split-out PCR)화형광원위잡교(FISH)방법진행험증.결과 재356례AML환자중상응융합기인양성자172례,양성솔위48.31%,고우핵형분석상응염색체역위검출솔(31.46%)(x2=70.314,P<0.01).재소견화난이식별적염색체역위중,RT-nPCR비핵형분석、FISH경구유우세(x2=96.074,P<0.01).결론 RT-nPCR가편첩、유효、준학지검측AML환자융합기인이상,작위AML초사적검측수단위질병진단급료효판정제공중요의거,동시야위미소잔류병감측급예후평고제공중요신식.
Objective To investigate the clinical value of multiplex nested reverse transcription PCR (RT-nPCR) in screening acute myeloid leukemia (AML) fusion genes.Methods A novel multiplex RT-nPCR assay was developed to detect 16 AML-related fusion genes (AML1-EVI1,AML1-ETO,AML1MDS1,AML1-MTG16,MLL-AF9,MLL-AF6,MLL-AF10,MLL-ENL,MLL-MLL,PML-RARα,PLZFRARα,NPM1-RARα,CBFB-MYH1 l,DEK-CAN,SET-CAN and TLS-ERG) according to 2008 WHO classification of AML.The chromosome reciprocal translocations of 356 AML cases were detected by multiplex RT-nPCR and karyotyping.The positive samples were further confirmed by split-out PCR and FISH.Results The fusion genes were detected in 172 patients with the positive detection rate of 48.31%(172/356),which was higher than that of karyotyping (31.46%) (x2=70.314,P<0.01).Multiplex RT-nPCR is superior to karyotyping and FISH in identifying the rare,cryptic chromosome translocation (x2=96.074,P<0.01).Conclusion The multiplex RT-nPCR used in this study can quickly,effectively and accurately screen the fusion genes in AML patients,which can provide important evidence for assessing diagnosis and treatment,and also provide necessary information for minimal residual disease (MRD) and prognosis.